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Abstract
Background: We recently identified a role for the muscle-specific ubiquitin ligase MuRF1 in right-sided heart failure
secondary to pulmonary hypertension induced by chronic hypoxia (CH). MuRF1−/− mice exposed to CH are resistant
to right ventricular (RV) dysfunction whereas MuRF1 Tg +mice exhibit impaired function indicative of heart failure. The
present study was undertaken to understand the underlying transcriptional alterations in the RV of MuRF1−/− and
MuRF1 Tg +mice.
Methods: Microarray analysis was performed on RNA isolated from the RV of MuRF1−/−, MuRF1 Tg+, and wild-type
control mice exposed to CH.
Results: MuRF1−/− RV differentially expressed 590 genes in response to CH. Analysis of the top 66 genes (> 2-fold
or < − 2-fold) revealed significant associations with oxidoreductase, transcription regulation, and transmembrane
component annotations. The significant genes had promoters enriched for HOXD12, HOXC13, and RREB-1 protein
transcription factor binding sites. MuRF1 Tg + RV differentially expressed 150 genes in response to CH. Analysis of
the top 45 genes (> 3-fold or < − 3-fold) revealed significant associations with oxidoreductase-metabolic, glycoprotein-
transmembrane-integral proteins, and alternative splicing/splice variant annotations. The significant genes were
enriched for promoters with ZIC1 protein transcription factor binding sites.
Conclusions: The differentially expressed genes in MuRF1−/− and MuRF1 Tg + RV after CH have common functional
annotations related to oxidoreductase (including antioxidant) and transmembrane component functions. Moreover,
the functionally-enhanced MuRF1−/− hearts regulate genes related to transcription, homeobox proteins, and kinases/
phosphorylation. These studies also reveal potential indirect effects of MuRF1 through regulating Rreb-1, and they
reveal mechanisms by which MuRF1 may transcriptionally regulate anti-oxidant systems in the face of right heart
failure.
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Background
Right ventricular heart failure is the most frequent cause
of death in patients with pulmonary arterial hypertrophy
(PAH) [1, 2]. In general, chronic hypoxia (CH) in the lungs
induces an elevation in pulmonary artery pressures, in-
creasing the afterload in the right ventricle. In response,
right ventricular (RV) remodeling results, possibly includ-
ing maladaptive hypertrophy. Recent reviews have outlined
the molecular and cellular drivers of right ventricular
remodeling in chronic pressure overload, including the
induction of cardiomyocyte cell death, increases in collagen
synthesis and decreases in collagen degradation, decreases
in capillary density and a metabolic shift to glycolysis [3].
Rho-kinase [4], adrenergic signaling [5] and altered angio-
genesis have been reported to play roles in the pathogenesis
of RV remodeling at the molecular level. Maladaptive RV
hypertrophy characteristically exhibits a shift to aerobic
glycolysis mediated by FOXO1 [6] and c-Myc [7]. Beyond
this, little is currently known about the molecular regula-
tion of these underlying mechanisms that occur during
PAH-induced RV heart failure.
The muscle-specific ubiquitin ligase Muscle Ring Finger-1
(MuRF1) regulates both physiological and pathological
hypertrophy and metabolism by interacting with specific
transcription factors that mediate these processes. MuRF1
interacts with and inhibits serum response factor [8],
which is upregulated in pathological pressure overload-in-
duced hypertrophy. As such, MuRF1−/− mice exhibited
exaggerated cardiac hypertrophy after transaortic constric-
tion in vivo [8]. MuRF1 interacts with the c-Jun transcrip-
tion factor in a proteasome-dependent manner to inhibit
downstream AP1 activity, implicated in inhibiting IGF-1
signaling [9]. Consistent with this, MuRF1−/− mice volun-
tarily ran farther and faster without training, improving
even more after training compared to wild-type mice [9].
The mechanisms by which cardiomyocyte MuRF1 inhibits
the PPARalpha and TRalpha nuclear receptors appear to
involve multi-mono-ubiquitination, resulting in changes
in metabolism in vivo [9, 10].
Given transcriptional regulation by MuRF1 in cardio-
myocytes, we recently hypothesized a role for MuRF1 in
the pathophysiology of right ventricle heart failure [11].
We exposed MuRF1−/− and cardiomyocyte-specific
MuRF1 transgenic (MuRF1 Tg+) mice to CH, resulting
in an elevated pulmonary artery pressure/resistance and
measured functional and morphological responses [11].
We found that MuRF1−/− mice exhibited greater RV
growth compared to wild-type mice but were resistant
to CH-induced changes in ejection fraction. As such, the
overall output in MuRF1−/− hearts provided significantly
increased perfusion to skeletal muscle compared to sibling
wild-type mice [11]. In contrast, MuRF1 Tg +mice exhib-
ited similar patterns in RV weight compared to wild-type
mice in response to CH, but there was a reduced ejection
fraction, indicative of a maladaptive dilated phenotype
(heart failure), consistent with the significant decreases
in skeletal muscle perfusion [11]. The present study was
undertaken to understand the underlying transcriptional
alterations that occur during CH in the right ventricle
of MuRF1−/− and MuRF1 Tg + mice using microarray
analysis.
Methods
MuRF1−/− and αMHC transgenic MuRF1 mice and the
hypoxia-induced pulmonary hypertension model of right
sided heart failure
MuRF1−/− and MuRF1 Tg mice and their strain-match
wild-type controls (previously described [8, 12]) were
shipped to the University of New Mexico. Following a
week-long quarantine, mice maintained in standard shoe-
box cages were moved to either control or normobaric
hypoxia chambers with continuous access to food and
water ad libitum throughout. The hypoxia chamber was
set at 10.0% oxygen (partial pressure of oxygen approxi-
mately 65 mmHg in Albuquerque, NM) and monitored
both by a digital feedback control system (Biospherix,
Parish, NY) as well as by a secondary O2/CO2 monitor
(O2Cap, OxiGraf, Inc.; Mountain View, CA), as recently
described [11]. Hypoxia exposure lasted 3 weeks with
twice-weekly cage changes and standard 12 h light:dark
cycle. Procedures were conducted under full isoflurane
anesthesia to minimize or eliminate risk of pain and
discomfort. Mice were anesthetized with isoflurane and
were euthanized by exsanguination, followed by rapid
removal of the heart into ice-cold phosphate-buffered
saline. The RV free wall was dissected away from the
rest of the heart, as previously described [13]. Mice were
bred at the University of North Carolina at Chapel Hill and
all the hypoxia procedures were conducted at the University
of New Mexico with full approval of the UNC-Chapel Hill
and University of New Mexico Institutional Animal Care
and Use Committees and were carried out in compliance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Microarray assay and statistical analysis
Microarrays were performed on RNA isolated from RV
tissue from animals challenged with hypoxia. At least
three independent samples were assayed from each of the
four experimental groups MuRF1−/− (N= 5), its strain
matched wild-type MuRF1+/+ (N = 6), MuRF1 Tg + (N= 3),
and its strain-matched wild type (N = 3). Gene expression
assay was performed using Agilent Whole Mouse 4 × 44 k
multiplex format oligo arrays (014868, Agilent Technologies,
Santa Clara, CA) following the Agilent 1-color microarray-
based gene expression analysis protocol. Data were obtained
using Agilent Feature Extraction software (version 12), using
the 1-color defaults for all parameters. The Agilent Feature
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Extraction software performed error remodeling, adjusting
for additive and multiplicative noise. To determine differen-
tially expressed genes between groups, an ANOVA with
multiple test correction (FDR q-value) was performed using
Partek Genomics Suite software (version 6.6). Only one gene
for MuRF1−/− and 6 genes for MuRF1 Tg + passed the FDR
q-value < 0.05 cutoff; therefore, the set of differentially
expressed genes was expanded to include genes from the
ANOVA analysis with an unadjusted p-value < 0.01 (see
Additional file 1: Table S1 and Additional file 2: Table S2).
To minimize inclusion of false positives, genes with fold
changes greater than 2 and less than − 2 (for MuRF1−/− vs.
MuRF1+/+) or greater than 3 and less than − 3 (for MuRF1
Tg + vs. MuRF1+/+) were selected for downstream bioinfor-
matic analyses. The differential expression of a subset of
selected genes was confirmed by RT-PCR. The MAIME-
compliant data were submitted to Gene Expression
Omnibus and assigned the accession #GSE82345 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=sfavmocq-
trupnan&acc=GSE82345, currently embargoed/not publicly
available).
Bioinformatics resources and analytic tools used and
retrieval of public microarray data
TRANSFAC® FMatch was used to analyze transcrip-
tion factors (https://portal.biobase-international.com,
GeneExplan GmbH). The TRANSFAC MATRIX TABLE,
Release 2016.2 was used as the matrix library. To minimize
false-positive matches, the matrix file vertebrate_non_
redundant_minFP was used for transcription factor bind-
ing sites prediction, using cut-off criteria to minimize
false-positives, and a p-value threshold set at 0.01. The
significant gene sets for the MuRF1−/− (66 unique genes)
and MuRF1 Tg + (45 unique genes) were used in the
STRING analysis. Duke Gather Literature Net. Genes
were analyzed at http://changlab.uth.tmc.edu/gather/ via
Literature Net. STRING database. The STRING database
(STRING Consortium, Swiss Institute of Bioinformatics,
Zurich, Switzerland) of known and predicted protein-pro-
tein interactions (https://string-db.org/) includes direct
(physical) and indirect (functional) associations aggregated
from other (primary) databases [14–16]. The significant
gene sets for the MuRF1−/− (66 unique genes) and
MuRF1 Tg + (45 unique genes) were used in the STRING
analysis. The MuRF1−/− significant networks contained
26 nodes (vs. expected 3 nodes), 74 edges, average node
degree 5.69, with a clustering coefficient of 0.735. The
MuRF1 Tg + significant networks contained 26 nodes, 75
edges (28 expected), average node degree 5.77 and a clus-
tering coefficient of 0.696. The Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.8
Functional Annotation Bioinformatics database was
used to analyze differentially expressed genes (https://
david.ncifcrf.gov/) [17, 18]. Analysis of gene lists (gene
symbols) were uploaded using the gene accession conver-
sion tool and analyzed using Disease (OMIM_Disease),
Functional Categories (COG_Ontology, UP_Keywords, UP_
SEQ_FEATURE) Gene Ontology (GOTERM_BP_DIRECT,
GOTERM_CC_DIRECT, GOTERM_MF_DIRECT), Path-
ways (BBID, BIOCARTA, KEGG PATHWAY) and Protein
Domains (INTERPRO, PIR_SUPERFAMILY, SMART).
Microarray data retrieval and experimental design. The
SuHx model of severe angio-obliterative pulmonary artery
hypertension and RV failure was used for male Sprague-
Dawley rats receiving a single subcutaneous injection of
SU5416 (20 mg/kg) prior to 4 weeks of hypoxia [2].
Microarray analysis (Agilent whole rat genome 4 × 44 k
microarray slide, Agilent Technologies, Wilmington,
DE) was performed on snap-frozen right heart tissues
[2]. Study datasets were retrieved from the publicly
available NCBI Gene Expression Omnibus (GEO Dataset_
GSE42579). Microarray replicates included 12 hypoxia
and 8 normoxia from 6 biological replicates per group
(hypoxia, normoxia). The GEO2R tool was used to down-
load the ID, adj. p value, p value, t value, B value, log fold
change (logFC), gene symbol, gene title, and gene ID of
the differentially expressed genes for further analysis and
comparison.
RT qPCR analysis of mRNA expression
Total RNA was isolated using RNeasy Mini kits (QIAGEN,
Valencia, CA) according to the manufacturer’s protocols.
Determination of gene expression was performed using
either a two-step RT-qPCR reaction [8, 19] or a one-step
RT-qPCR reaction, as previously described [20]. For the
two-step reaction, cDNA was made using iScript cDNA
Synthesis kit, according to the manufacturer’s protocol
(BioRad, Hercules, CA, Cat# 1708890). One microliter of
the resulting cDNA product was then amplified in a 20-μl
final volume using the TaqMan® Universal PCR Master
Mix. Each reaction included 1 μl of mouse specific
TaqMan probes for MuRF1 (Mm01185221_m1), Atp2b2
(Mm00437640_m1), Elovl7 (Mm00512434_m1), Gbp3
(Mm00497606_m1), Cxcl9 (Mm00434946), Myl1
(Mm00659043_m1), Casq1 (Mm00486725_m1), GAPDH
(glyceraldehyde-3-phosphate dehydrogenase, Probe
Mm99999915_g1), or 18S (Hs99999901_s1) in triplicate
(ThermoFisher Scientific, Inc., Waltham, MA). The
relative expression of mRNA (ΔΔCT algorithm) was
determined using GAPDH or 18S as an internal sample
loading control.
Statistical analysis
For qRT-PCR analyses, Student’s t-test was performed to
determine significant differences between groups. All
statistics were performed using GraphPad Prism (La Jolla,
CA, Version 7.01) with p values < 0.05 considered statisti-
cally significant.
Oakley et al. BMC Medical Genetics  (2018) 19:175 Page 3 of 17
Results
To understand MuRF1’s role in the pathophysiology of
CH-induced right heart failure, we performed microarray
analysis on right ventricle tissue from MuRF1−/− and
MuRF1 Tg +mice (and sibling wild-type controls) after
three weeks of CH. Analysis of MuRF1−/− and MuRF1+/+
RV tissue by microarray analysis identified 590 genes to
be significantly different from wild-type controls (ANOVA,
p < 0.01) (Fig. 1a, Additional file 1: Table S1). We identified
the top 35 unique genes increased (> 2-fold) and top 31
unique genes decreased (<− 2-fold) (Fig. 1b) and analyzed
them for common transcription factors that may be
responsible for the differential regulation of the MuRF1−/−
mice using TRANSFAC® FMatch Analysis. We identified
three (3) transcription factors that were enriched in signifi-
cantly altered gene promoters in MuRF1−/− hypoxia-chal-
lenged RV compared to wild-type controls (left, Fig. 1c).
These transcription factors are listed by the number of the
binding sites found in the transcription factor sequences
(sites/sequence ratio) reflecting how common these sites
were for each transcription factor. The Homeobox D12
(HOXD12), Homeobox C13 (HOXC13), and the Ras
Responsive Element Binding Protein 1 (RREB-1) were
enriched 10-, 6.5- and 6.5-fold, respectively (Fig. 1c). Of
the 66 significant genes used in the FMatch analysis, 15, 8
and 2 of these genes were associated with HOXD12,
HOXC13 and RREB-1, respectively (Fig. 1c).
To understand how the differentially expressed genes
in the MuRF1−/− right ventricle are known to interact, we
performed a STRING analysis to identify relationships
that had been reported between these gene products in
the literature (Fig. 1d). We identified significantly more
interactions than would be expected by chance. Specif-
ically, the network had 26 modes and 74 edges compared
to the expected 3 edges due to chance. The functional
enrichments identified by STRING Gene Ontology (GO)
included the regulation of transcription, gene expression
and RNA metabolic processes (Fig. 1e). Overall, HOXD12
had the most interactions (20), while MTF2 and MLL4
had 9 and INTS12 had 6, demonstrating the importance
of HOXD12 among these proteins based on our current
knowledge of these genes.
To determine the functional significance of the 66
differentially expressed genes from the MuRF1−/− right
ventricle in more detail, we performed functional annota-
tions using both STRING and DAVID. STRING analysis
of functional categories identified regulation of transcrip-
tion, gene expression, and RNA metabolism as the signifi-
cant pathways with low false discovery rates (Fig. 1e).
DAVID analysis detailed these functions, identifying five
functional clusters across several databases (Fig. 2a). Func-
tional annotation identified 30 genes (Fig. 2a, far left) that
exhibited reduced enrichment in five clusters, including
Homeobox-related genes (cluster 1), genes involved in
oxidoreductase (cluster 2), genes involved in phosphor-
ylation/kinase activity (cluster 3), genes involved in the
regulation of transcription (cluster 4), and genes involved
in the transmembrane components (cluster 5) (Fig. 2a).
We validated the differential expression of several genes in
the MuRF1−/− right ventricle after CH, including MuRF1,
Atp2b2, Elovl7, Gbp3 and Cxcl9 mRNA by RT-qPCR ana-
lysis (Fig. 2b and Additional file 3: Figure S1). Together,
these results demonstrate that 3 weeks of CH-induced
changes in the MuRF1−/− right ventricle to alter functions
associated with homeobox proteins (associated with gene
expression), oxidoreductase processes, kinases/phos-
phorylation, transcriptional regulation and transmembrane
components.
Analysis of MuRF1 Tg + and MuRF1+/+ RV tissue by
microarray analysis identified 150 genes as significantly
different from wild-type controls (ANOVA, p < 0.01)
(Fig. 3a, Additional file 2: Table S2). We identified the
top 27 unique genes increased (> 3-fold) and top 18
unique genes decreased (<− 3-fold) (Fig. 3b) so that we
could identify the common transcription factors that
may be responsible for the differential regulation of
MuRF1Tg + mice using TRANSFAC® FMatch Analysis.
Analysis of these 45 genes identified that they were
enriched with promoter regions recognized by the ZIC1
(ZInc finger protein of the Cerebellum (Zic) Family
Member 1) protein transcription factor in MuRF1Tg + −
hypoxia-challenged RV compared to wild-type controls
(Fig. 4a). The 2.6-fold enrichment in ZIC1 protein pro-
moter sites (p = 6.76549e-03) was based on the significantly
altered genes Jakmip3 (Janus Kinase and Microtubule Inter-
acting Protein 3), Cyp2b13 (Cytochrome P450 Family 2
Subfamily B Member 6), Gucd1 (Guanylyl Cyclase Domain
Containing 1), Kansl1l (KAT8 Regulatory NSL Complex
Subunit 1 Like) and Rab3gap1 (RAB3 GTPase Activating
Protein Catalytic Subunit 1) genes (Fig. 4a).
To identify how the genes that were differentially
expressed in the MuRF1 Tg + right ventricle compared to
wild-type controls after three weeks of CH, we performed
a STRING analysis to identify relationships that had been
reported between these gene products in the literature
(Fig. 4b). Specifically, the network had 26 modes and 75
edges compared to the expected 28 edges due to chance
(PPI enrichment p-value = 3.27e-13). The functional
enrichments identified by STRING Gene Ontology (GO)
included chromatin modification, histone modification
and regulation of gene expression among other related
functions (Fig. 4c). Overall, ZIC1 protein had 6 interac-
tions across the STRING network and GL1 and GL13
had 9 and 13 interactions with the network, respectively,
demonstrating the importance of ZIC1 within these
proteins in the literature.
We analyzed the 45 differentially expressed genes from
the MuRF1 Tg + right ventricle after 3 weeks of CH using
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Fig. 1 Differential gene expression of MuRF1−/− right ventricle after three weeks CH exposure. a Summary of how differentially expressed genes in
hypoxia-challenged MuRF1−/− RV tissue compared to MuRF1+/+ were identified. b Top 35 increased unique genes (> 2-fold) and top 31 decreased
unique genes (<− 2-fold) compared to MuRF1+/+ hearts. Asterisk (*) designates same/related sequence for duplicate gene name. c Identification of
transcription factors with binding sites of top 35 increased and top 31 decreased genes using TRANSFAC® FMatch. The number of genes in dataset
and enrichment (sites/sequence ratio) for each transcription factor is calculated to the right. d STRING analysis of differentially expressed genes for
known interactions and e STRING analysis pathway ID statistics. MuRF1−/−: N = 5 biological replicates; MuRF1+/+: N = 6 biological replicates
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Fig. 2 (See legend on next page.)
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DAVID analysis to understand the biological relevance
of the gene set. We found five clusters, including
oxidoreductase-metabolic (cluster 1), glycoprotein-
transmembrane-integral proteins (cluster 2), cell mem-
brane/cell junction (cluster 3), signal peptide, glycosylation
(cluster 4) and alternative splicing/splice variant (clus-
ter 5) (Fig. 5a). We validated the differential expression
of several genes in the MuRF1 Tg + right ventricle after
CH, including MuRF1, Casq1 and Myl1 mRNA by RT-
qPCR analysis (Fig. 5b). Analysis of the 45 differentially
expressed genes from the MuRF1 Tg + right ventricle
for their relationships in the literature [21] identified
12 groups, including links with PPAR binding protein
(PPARBP), regulators of G-protein signaling (RGS5, RGS8,
RGS12, RGS14, RGS20) and v-ros UR2 sarcoma virus
oncogene (ROS1) (Additional file 4: Figure S2).
Comparison of the functional categories identified in
the CH-challenged MuRF1−/− right ventricles (vs. wild
type) (Fig. 2a) and the MuRF1 Tg + right ventricles (vs.
wild type) (Fig. 5a) demonstrates overlapping and unique
functional regulation in each model (Table 1). Both the
MuRF1−/− and MuRF1 Tg + hearts have differential regu-
lation of oxidoreductase functions and transmembrane
component proteins (Table 1). The MuRF1−/− model
uniquely regulated genes associated with homeobox
proteins, kinase/phosphorylation, and transcriptional
regulation (Table 1, left column) while the MuRF1 Tg +
model uniquely regulated genes associated with signal
peptide/glycosylation and alternative splicing (Table 1,
right column).
To give context to our identification of MuRF1-regulated
genes in the right ventricle after 3 weeks of CH, we identi-
fied a previous study that performed microarray analysis of
the right ventricle after CH [2]. We obtained the publicly
available data from NCBI GEO to identify the genes differ-
entially expressed in right heart failure induced by CH
(Fig. 6). Of the 25,241 defined genes (Fig. 6a), we identified
the top 50 genes increased (> 4.9-fold) and top 50 genes de-
creased (<− 3.9-fold) compared to controls (Additional file 5:
Figure S3) and we analyzed these genes using TRANSFAC®
FMatch Analysis to identify transcription factors that bind
promoters of the significantly altered hypoxia-challenged
RV (Fig. 6b). The most enriched transcription factor protein
sites included the CREB binding protein (CPBP, 33.46-fold
enriched), Zinc Finger Protein 333 (ZNF333, 20-fold
enriched), Sex Determining Region Y (SRY) (18.32-fold
enriched), and the Nuclear Factor of Activated T-Cells
2 (NFATc2, 11.66-fold enriched) (Fig. 6b). Analysis of the
100 differentially expressed genes from the CH-challenged
right ventricle for their relationships in the literature [21]
identified 8 groups, including links with PPAR binding
protein (PPARBP), regulators of G-protein signaling
(RGS5, RGS8, RGS12, RGS14, RGS18, RGS20) and v-ros
UR2 sarcoma virus oncogene (ROS1) (Additional file 6:
Figure S4). This analysis provides a context of the tran-
scriptional regulation of the RV remodeling that occurs in
response to pulmonary hypertension induced right heart
failure, demonstrating the transcriptional control involved
(Fig. 6b) and the associated connections with proteins in
the literature (Additional file 6: Figure S4). When we com-
pared the TRANSFAC Match Analysis identified in the
CH-challenged MuRF1−/− right ventricles (vs. wild type)
(Fig. 1c) with the MuRF1 Tg + right ventricles (vs. wild
type) (Fig. 4a) and hypoxia-induced right heart failure (Fig.
6b), Rreb-1 was identified as a common transcription
factor (Table 2). Finally, considerable overlap was seen in
Literature Net analysis of the MuRF1−/− significant genes
after CH (vs. wild type) (Additional file 4: Figure S2) and
the significant genes found in wild-type rat right hearts
after CH (Additional file 6: Figure S4), with almost
complete overlap (PPARBP, RGS proteins, and ROS1).
Discussion
We recently identified that MuRF1−/− mice were resistant
to weeks of CH-induced changes in RV ejection fraction
and volume (systolic and diastolic) and exhibited signifi-
cantly increased skeletal muscle perfusion, consistent with
better cardiac function compared to wild-type mice [11].
In the present study, we analyzed the MuRF1−/− and
MuRF1 Tg + right ventricle transcriptome by microarray
analysis to determine the role of cardiomyocyte MuRF1 in
response to CH and resulting pulmonary hypertension.
The differentially expressed transcripts in the MuRF1−/−
hearts (vs. wild type) were enriched by up to 10-fold
for HOXD12, HOXC13 and RREB-1 protein promoter
regions (Fig. 1c). The role of HOXD12 and HOXC13
in the heart or muscle has not been previously reported to
our knowledge; however, their role in transcription and
gene expression (as are other homeodomain proteins) is
well-annotated in gene ontology (Fig. 1e). Our analysis of
a publicly available dataset from a rat model of CH expos-
ure also identified the Rreb-1 (enriched 4.25-fold) as a
transcription factor associated with differentially regulated
genes, among other transcription factors (e.g., SRY, CRX,
(See figure on previous page.)
Fig. 2 Functional annotation of differentially expressed genes in MuRF1−/− right ventricle after three weeks CH exposure. a. Hypercluster analysis
of differentially expressed MuRF1−/− genes in the right ventricle after hypoxia challenge using the DAVID v6.8 Functional Annotation Bioinformatics
database. Differentially expressed gene symbols are on the left, functional categories along the top (database source in parentheses). The cluster fold
enrichment is color-coded (key in lower right). b. Reverse transcriptase quantitative PCR analysis of MuRF1−/− hearts of differentially expressed genes
MuRF1, Atp2b2, and Elovl7 mRNA in the right ventricle
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MAF, SMAD4) (Fig. 6b). There are several differences
in the experimental design of this previous study that
used Sprague-Dawley rats (vs. mice in the present
study) and pulmonary artery hypertension induced by a
single subcutaneous SU5416 (20 mg/kg) injection and
4 weeks of hypoxia (vs. 3 weeks of hypoxia only) [2].
RREB-1 transcription factor binds specifically to the
RAS-response elements (RRE) of gene promoters and acts
as a coregulatory factor for ninety-one (91) transcription
factors in various tissues [22]. In the heart, the RREB-1
protein notably binds with MEF-2, POU3F2, SRF,
PPARalpha/RXRalpha, GR and E2F. While the role of
RREB-1 has not been investigated directly in the heart,
these seven transcription factors have well-defined roles in
A B
Fig. 3 Differential gene expression of MuRF1 Tg + right ventricle after three weeks CH exposure. a. Summary of how differentially expressed genes in
hypoxia-challenged MuRF1Tg+ right ventricles were identified. b. Top 27 increased unique genes (> 3-fold) and top 18 decreased unique genes (<− 3-fold)
compared to wild-typeMuRF1Tg+ RV tissue. Asterisk (*) designates transcript variant for duplicate gene name. MuRF1 Tg+: N= 3; strain-matched wild type: N=3
Oakley et al. BMC Medical Genetics  (2018) 19:175 Page 8 of 17
heart failure. MEF-2 and SRF, in particular, are known to
play critical roles in pathological hypertrophy and are part
of the “fetal gene” response in pressure overload-induced
heart failure [23]. PPARalpha/RXRalpha have critical roles
in regulating fatty acid metabolism in cardiomyocytes
and in the context of heart failure have been proposed
to play roles in the shift in substrate utilization in heart
failure [24].
These findings are notable given what is known about car-
diac MuRF1 activity according to the literature. In studies of
MuRF1−/− mice challenged with pressure overload-induced
hypertrophy via transaortic constriction, MuRF1−/− mice
experienced enhanced hypertrophy (cardiomyocyte growth)
and decreased SRF-regulated gene expression (fetal genes)
[8]. These studies found that MuRF1 immunoprecipitated
specifically with SRF and directly inhibited cardiomyocyte
SRF activity [8]. Similarly, cardiomyocyte MuRF1 has been
reported to interact directly with PPARalpha to inhibit its
activity, with MuRF1−/− hearts having a five-fold increase in
PPARalpha activity [25]. In these studies, increasing MuRF1
A
B
C
Fig. 4 Functional annotation of differentially expressed genes in MuRF1 Tg + right ventricles after three weeks CH exposure. a. Identification of
ZIC1 protein binding sites based on binding sites in 5 of the differentially expressed genes in MuRF1 Tg + heart (Jakmip3, Cyp2b13, Gucd1, Kansl1l,
Rab3gap1). The number of genes in dataset and enrichment (sites/sequence ratio) for each transcription factor is calculated to the right. b. STRING
analysis of the top 27 genes increased (> 3-fold) and top 18 genes decreased (<− 3-fold) listed in Fig. 3b. c. Functional annotation of differentially
expressed MuRF1 Tg + right ventricle by STRING analysis
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expression demonstrated enhancement of PPARalpha nu-
clear export, dependent upon specific lysines adjacent to nu-
clear export sequences found to be mono-ubiquitinated
[25]. In additional to MuRF1’s regulation of SRF and PPAR-
alpha, cardiac MuRF1 and MuRF2 have been reported to
support transcription factor E2F1 in microarray studies,
confirmed by chromatin IP studies in the context of devel-
opmental cardiac growth [26, 27]. Since pulmonary (RV)
hypertension has numerous parallels with left ventricular
pressure overload-induced hypertrophy, the present study
may suggest that MuRF1’s regulatory effects on SRF may
contribute to the phenotype observed. Taken together, the
present study suggests that MuRF1’s regulation of SRF,
PPARalpha, and E2F1 may be due to MuRF1’s broader regu-
lation of cotranscription factors such as Rreb-1, given
Rreb-1’s established connection with SRF, PPARalpha and
E2F1 in other tissues [22].
Beyond the evidence linking MuRF1 to the regulation
of transcription, the differentially expressed genes in the
MuRF1−/− right ventricle after CH were related to
A
B
Fig. 5 Functional annotation of differentially expressed genes in MuRF1 Tg + hearts compared to wild-type controls. a. Hypercluster analysis of
differentially expressed MuRF1−/− genes in the right ventricle after hypoxia challenge using the DAVID v6.8 Functional Annotation Bioinformatics
database. Differentially expressed gene symbols are on the left, functional categories along the top (database source in parentheses). The cluster
fold enrichment is color-coded (key in lower left). b. Reverse transcriptase quantitative PCR analysis of MuRF1−/− hearts of differentially expressed
genes MuRF1, Casq1, and Myl1 mRNA in the right ventricle
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oxidoreductase functions. Oxidoreductases are enzymes
that catalyze oxidoreduction reactions and have important
roles in aerobic and anaerobic metabolism and the
utilization of NAD+/NADH. In the heart, catalase is an ox-
idoreductase that acts on H2O2, breaking it down to harm-
less hydrogen and water [28, 29]. In the present study, the
MuRF1−/− right ventricle had several differentially
expressed genes related to the oxidoreductase system
(Adh1, Aasdh, Pam, Xdh) (Fig. 2a). Alcohol dehydrogen-
ase 1 (Adh1) has been identified in the heart to have im-
portant antioxidant roles in collaboration with catalase
[30]. Expression of aminoadipate-semialdehyde dehydro-
genase (Aasdh) is highest in the brain, followed by
heart and skeletal muscle [31]. In the heart, the mem-
brane bound peptidylglycine alpha-amidating monooxy-
genase (Pam) has been implicated in the shaping of
atrial secretory vesicles related to the secretion of
pro-ANP [32]. Cell injury from hyperoxia was associ-
ated with increased superoxide radicals, which has been
associated with xanthine dehydrogenase (Xdh) activity
in heart [33]. MuRF1−/− right ventricles also had dif-
ferentially expressed genes (Araf, Ip6K3, Nmrk2) associ-
ated with kinase activity (Fig. 2a). The role of raf
proteins, including A-Raf Proto- Oncogene, Serine/Threo-
nine Kinase (Araf), has been described in cardiac hyper-
trophy and cardiomyocyte survival, with antiapoptotic
activity independent of MKK and ERK activities [34, 35]. In-
ositol hexakisphosphate kinase 3 (Ip6K3) has been linked to
metabolism and lifespan in mice [36], while nicotinamide
riboside kinase 2 (Nmrk2) has critical roles in NAD metab-
olism in mammalian cells [37].
Cardiomyocyte MuRF1 has been indirectly linked to oxi-
doreductase functions in previous studies. Cardiomyocyte-
specific MuRF1 Tg +mice were challenged with an acute
cardiac ischemia reperfusion injury both ex vivo and in vitro
and demonstrated considerable resistance to injury and
functional defects [38]. One mechanism that could explain
this protection against acute hypoxia is MuRF1’s inhibition
of JNK signaling, mediated by MuRF1’s polyubiquitination
of phosphorylated c-Jun (subsequently degraded) [38].
Subsequent studies showed that MuRF1 Tg + heart
mitochondria generated significantly less (51–67% less)
ROS measured by H2O2 emission at baseline compared
to sibling wild-type control mitochondria [39]. How
MuRF1 reduces H2O2 emission is not known, but the
results from the current study may lend some insights.
We utilized the MuRF1 Tg + mice in present study
because of the limited redundancy that is known to
occur between MuRF1 and other MuRF family members
(MuRF2, MuRF3). This redundancy was initially suggested
by overlap of some binding partners (e.g., cardiac troponin
I [cTnI]) but not others (e.g., myosin light chain 2) [40].
The partial overlap between cardiac MuRF1, MuRF2 and
MuRF3 was also seen in nontargeted metabolomics studies
of baseline heart tissues [41]. As seen in previous studies
of MuRF1 Tg +mice challenged with pressure overload-in-
duced hypertrophy [12], CH resulted in significant de-
creases in RV weight and ejection fraction, indicating a
maladaptive dilated phenotype (heart failure) [11]. In
contrast to the MuRF1−/− mice challenged with CH
that resulted in improved skeletal muscle perfusion (vs.
wild-type mice), MuRF1 Tg + mice exhibited significant
decreases in skeletal muscle perfusion [11]. Identification
of transcription factors enriched in the differentially
expressed genes in the MuRF1 Tg + right ventricle in the
present study identified promoter regions that the ZIC1
protein binds (Fig. 4a). The ZIC1 protein is a transcrip-
tional activator described primarily in the development
and maturation of the cerebellum [42]. It has also been
reported to have a role in shear flow mechanotransduction
Table 1 Summary of DAVID functional annotation categories of significant genes. From Figure 3A (MuRF1-/-) and Figure 5A (MuRF1
Tg+) based off differentially expressed genes in Figure 2A and Figure 5A. Matching colors represent related categories found in
hearts lacking MuRF1 and hearts with increased cardiomyocyte MuRF1 post-hypoxia challenge compared to wildtype controls
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in osteocytes [43]. Functionally it retains nuclear GLI1
and GLI3 in the cytoplasm by binding the minimal
GLI-consensus sequence 5-TGGGTGGTC-3 [44]. Muta-
tions in Zic gene family members resulted in congenital
heart defects in both humans and mice [45]. The ZIC1
protein has also been shown to act as a protein transcrip-
tion factor upstream Pax3 in the induction of embryonic
neural crest [46]. While little is known about the ZIC1
protein in the heart, it has been linked to the homeobox
domain protein HOXA1 protein. Specifically, Hoxa1
null embryos revealed their regulation of genes in cardiac
NC precursors, including Hnf1b, Foxd3, and Zic1 [47].
Sumoylation regulates the nuclear localization and function
of closely related ZIC3 protein family members [48, 49].
Hypoxia-induced RV hypertrophy in cardiomyocyte-spe-
cific MuRF1 Tg +mice induced gene expression changes
A B
Fig. 6 Differentially expressed genes in a rat model of CH-induced pulmonary hypertension and right heart failure. a. Summary of how
differentially expressed genes in CH-induced rat heart failure resulted in top 50 increased genes (> 4.9-fold) and top 50 decreased genes (< 3.9-fold)
compared to normoxia using data from Drake, et al., 2013 [2]. Genes summarized in Additional file 4: Figure S2. b. Identification of transcription factors
with binding sites of top 50 increased and top 50 decreased genes. The number of genes in the dataset and enrichment (sites/sequence ratio) for
each transcription factor is calculated to the right
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functionally linked to oxidoreductase regulation. Of the five
differentially expressed genes in the MuRF1 Tg + post-CH
related to oxidoreductase regulation (Fig. 5a, far left
column), only one had clear roles in the heart. The Delta
4-Desaturase Sphingolipid 2 (Degs2) is an enzyme involved
in de novo ceramide synthesis. One study reported that
ethanol exposure upregulated Degs in rats and altered lipids
profiles that support beneficial cardioprotective and neuro-
protective effects of moderate ethanol consumption [50].
The role of DEGS2 in the heart is unknown. The Cyto-
chrome P450 Family 27 Subfamily B Member 1 (Cyp27b1),
also known as 25-Hydroxyvitamin D3 1-alpha-hydroxylase,
is responsible for the hydroxylation of calcifediol to
calcitriol (the bioactive form of vitamin D). Variants in Di-
acylglycerol Kinase Kappa (Dgkk) have been described in
association with hypospadias [51–54], but no functions in
the heart have been reported. The role of Cyp27b1 in the
heart is unknown. Detailed function of the Cytochrome
Table 2 Summary of transcription factors identified in the MuRF1-/- and MuRF1 Tg+ right ventricles (vs. wildtype) by TRANSFAC®
Match Analysis. From Figure 2C (MuRF1-/-) and Figure 4C (MuRF1 Tg+) based off differentially expressed genes in Figure 2B and
Figure 4B. Matching colors represent related transcription factors identified in hearts lacking MuRF1 and hearts with increased
cardiomyocyte MuRF1 post-hypoxia challenge compared to wildtype controls
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P450 Family 2 Subfamily B Member 13 (Cyp2b13) and
Arachidonate 12-Lipoxygenase, 12R Type (Alox12b) were
unavailable beyond the functional categorization by DA-
VID (Fig. 5a).
Hypoxia-induced RV hypertrophy in cardiomyocyte-
specific MuRF1 Tg +mice also induced gene expression
changes functionally linked to alternative splicing/splice
variants. Of the 16 differentially expressed genes in the
MuRF1 Tg + post-CH related to alternative splicing
(Fig. 5a, far right column), four stood out (Casq1, Myl1,
Erbb2ip, Pitx2). Calsequestrin 1 (Casq1) functions as a
calcium buffer in the heart with a role in calcium re-
lease by interactions with the ryanodine receptor, hav-
ing important implications for contractility [55–57].
Myosin Light Chain 1 (Myl1) is a GATA4 target gene
related to IGF-1 signaling in the context of pathological
hypertrophy stimuli [58]. The Erbb2 Interacting Protein
(Erbb2ip) is present in relatively high levels in the heart
and has been found to be down-regulated in heart biop-
sies from human failing hearts, with a role in attenu-
ated ERK signaling to negatively modulate cardiac
hypertrophy experimentally in mice [59]. Mutations in
the Paired Like Homeodomain 2 (Pitx2) gene in the heart
have been seen in the Tetralogy of Fallot and atrial fibrilla-
tion in patients [60–64]. Interestingly, Pitx2 was the only
gene in common between the set of 66 differentially
expressed genes in the MuRF1−/− hearts and the set of 45
differentially expressed genes in the MuRF1 Tg + hearts.
Pitx2 expression was induced in RV in mice lacking
MuRF1 and was repressed in response to MuRF1 overex-
pression, suggesting an exquisite sensitivity of this gene to
levels of MuRF1.The Fatty Acid Synthase (FASN aka C93)
gene was associated with lipid metabolism reprogramming
in arrhythmogenic RV cardiomyopathy [65], while hypoxia
has been associated with FASN-dependent free fatty acid
production [66–68]. Lastly, the RAB3 GTPase Activating
Protein Catalytic Subunit 1 (Rab3gap1) has been associ-
ated with cardiovascular risk (total cholesterol and HDL)
by GWAS association in Framingham Heart Studies [69],
with Rab3gap1 loci having associations with an increased
risk of SCD [70]. The remaining differentially expressed
genes in MuRF1 Tg + hearts after CH exposure associated
with alternative splicing (Ptpru, Svopl, Syt16, Ccp110, Jak-
mip3, Kansl1l) have not been functionally defined in heart
and/or cardiac disease to our knowledge.
Conclusions
Analysis of the top differentially expressed transcripts in
the MuRF1−/− right ventricle after CH revealed genes
involved in the regulation of transcription and oxidore-
ductase functions. Bioinformatic analysis suggested that
the differentially expressed genes in MuRF1−/− right
ventricle tissue were linked to HOX (homeobox) transcrip-
tion factors and Rreb-1. Analysis of the top differentially
expressed transcripts in the cardiomyocyte-specific MuRF1
Tg + − right ventricle after CH revealed genes involved
in the regulation of oxidoreductase-metabolic, glyco-
protein-transmembrane and alternative splicing func-
tions. Together, the MuRF1−/− and MuRF1 Tg + results
have common functional annotations related to oxidore-
ductase (including antioxidant functions) and transmem-
brane component functions (Table 1). These studies reveal
potential indirect effects of MuRF1 on known substrates
such as SRF and PPARalpha by regulation of Rreb-1. The
results also give insight into potential mechanisms by which
MuRF1 regulates antioxidant systems by transcriptionally
regulating genes related to oxidoreductase functions.
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